11 September 2026

ASX Market Announcements Office
Australian Securities Exchange

Baby Bunting Group Limited (ASX: BBN)

2026 Annual General Meeting

Attached is the Baby Bunting Group Limited Notice of 2026 Annual General Meeting and a sample of the related proxy form.

The 2026 Annual General Meeting will be held at 10.00am on Tuesday, 13 October 2026.

These documents have been authorised for release to ASX by the Company Secretary.

For further information, please contact:

Corey Lewis
Company Secretary
Ph: 03 8795 8169

Baby Bunting

Notice of 2026 Annual General Meeting

Baby Bunting Group Limited
ABN 58 128 533 693

Notice of 2026 Annual General Meeting

Notice is given that the Annual General Meeting of Baby Bunting Group Limited (Baby Bunting or the Company) will be held in person at **Cliftons Sydney, Level 13, 60 Margaret Street, Sydney** and will be available to view via live webcast at https://meetnow.global/BBN2026 at **10.00am (Sydney time) on Tuesday, 13 October 2026**.

Shareholders can submit questions in advance of the Meeting, ask questions online during the Meeting, and vote by appointing a proxy. Please note that shareholders viewing the Meeting via the live webcast will not be able to vote online and should submit their proxy in advance of the Meeting. All proxy appointments, whether submitted online or in hard copy, must be lodged by 10.00am (Sydney time) on Sunday, 11 October 2026.

Business

1. Annual Reports

To consider the Annual Report, the Financial Report, the Sustainability Report and the Reports of the Directors and of the Auditor for the year ended 28 June 2026.

2. Election of Directors

a. To re-elect Donna Player

Donna Player is retiring in accordance with the Company's Constitution and, being eligible, offers herself for re-election as a Director.

b. To elect Richard Vincent

Richard Vincent having been appointed a Director since the last annual general meeting is retiring in accordance with the Company's Constitution and, being eligible, offers himself for election as a Director.

3. Adoption of the Remuneration Report

To adopt the Remuneration Report for the year ended 28 June 2026.

The vote on this resolution is advisory only and does not bind the Company.

4. Approval of the grant of share rights to the CEO as deferred equity for his FY2026 Short Term Incentive payment

To consider and, if thought fit, pass the following as an ordinary resolution:

"That the grant of share rights to the Company's CEO, Mark Teperson, as deferred equity in respect of his FY2026 Short Term Incentive award, as described in the Explanatory Notes to this Notice of 2026 Annual General Meeting, be approved for all purposes, including for the purpose of ASX Listing Rule 10.14."

5. Approval of the grant of performance rights to the CEO under the Company's Long Term Incentive Plan

To consider and, if thought fit, pass the following as an ordinary resolution:

"That the grant of performance rights to the Company's CEO, Mark Teperson, under the Company's Long Term Incentive Plan, as described in the Explanatory Notes to this Notice of 2026 Annual General Meeting, be approved for all purposes, including for the purpose of ASX Listing Rule 10.14."

6. Approval of the Long Term Incentive Plan

To consider and, if thought fit, pass the following as an ordinary resolution:

"That, for the purposes of ASX Listing Rule 7.2 (Exception 13(b)), section 260C(4) of the *Corporations Act 2001* (Cth) and for all other purposes, shareholders approve the Company's Long Term Incentive Plan (**LTI Plan**), and the issue of securities under that LTI Plan, on the terms and conditions described in the Explanatory Notes to this Notice of 2026 Annual General Meeting."

Voting at the Meeting

Voting restrictions for Item 3 (Remuneration Report)

Item 3 is a resolution connected directly with the remuneration of members of the key management personnel (**KMP**) of the Company. The *Corporations Act 2001* (Cth) (**Corporations Act**) restricts KMP and their closely related parties from voting on such resolutions. 'Closely related party' is defined in the Corporations Act and includes a spouse, dependant and certain other close family members, as well as any companies controlled by the member of the KMP.

The Company will disregard any votes cast on the proposed resolution in Item 3:

- by or on behalf of members of the KMP, details of whose remuneration are included in the 2026 Remuneration Report and closely related parties of those persons, regardless of the capacity in which the vote is cast; and
- as a proxy by or on behalf of a person who is a member of the KMP at the date of the Annual General Meeting (or their closely related parties).

However, the Company will not disregard votes if they are cast on Item 3 by:

- a person as proxy for a person entitled to vote on the resolution, in accordance with a direction given to the proxy or attorney to vote on the resolution in that way; or
- the Chair of the Meeting as proxy for a person entitled to vote and the Chair has received express authority to vote undirected proxies as the Chair sees fit, even though the resolution is connected with the remuneration of members of the KMP.

Voting restrictions for Items 4, 5 and 6 (Grant of rights and approval of the LTI Plan)

The Company will disregard any votes cast in favour of the proposed resolution:

- in Item 4 or Item 5 by or on behalf of the Company's CEO, Mark Teperson, or any person referred to in ASX Listing Rules 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the Company's equity incentive plans, or an associate of that person or persons; and
- in Item 6 by or on behalf of a person eligible to participate in the Long Term Incentive Plan, or an associate of that person.

However, the Company will not disregard the vote as a result of these restrictions if it is cast:

- as a proxy or attorney for a person entitled to vote in accordance with the directions given to the proxy or attorney to vote on the resolution in that way; or
- by the Chair of the Meeting as proxy or attorney for a person entitled to vote, in accordance with a direction given to the Chair to vote as the Chair decides, even though the resolution is connected with the remuneration of a member of the KMP; or
- by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and
  - the holder votes on the resolution in accordance with the beneficiary's directions.

In addition to the voting restrictions referred to above, as required by the Corporations Act, a vote cast as a proxy on the proposed resolutions in Item 4, 5 or 6 by a member of the Company's KMP at the date of the Annual General Meeting and closely related parties of members of the KMP will be disregarded, other than where the vote is cast:

- as proxy for a person entitled to vote in accordance with a direction on the proxy form; or
- by the Chair of the Meeting as proxy for a person entitled to vote and the Chair has received express authority to vote undirected proxies as the Chair sees fit.

Chair's voting intention for undirected proxies

The Chair of the Annual General Meeting intends to vote undirected proxies (where the Chair has been appropriately authorised, having regard to the Voting Restrictions above) in favour of each item of business.

Entitlement to attend and vote

The Board has determined that, for the purposes of the Meeting (including voting at the Meeting), shareholders are those persons who are registered as holders of the Company's shares at 10.00am (Sydney time) on 11 October 2026.

Eligible shareholders may attend the Meeting, ask questions and vote in person at **Cliftons Sydney, Level 13, 60 Margaret Street, Sydney**. Registration will commence at 9.30am (Sydney time).

Please note that shareholders viewing the Meeting via the live webcast will **not be able to vote online** and should submit their proxy in advance of the Meeting. All proxy appointments, whether submitted online or in hard copy, must be lodged by 10.00am (Sydney time) on Sunday, 11 October 2026.

Voting by proxy

A shareholder who is entitled to attend and cast a vote at the Meeting may appoint a proxy. A proxy need not be a shareholder. A person can appoint an individual or a body corporate as a proxy. If a body corporate is appointed as a proxy, it must ensure that it appoints a corporate representative in accordance with section 250D of the Corporations Act to exercise its power as a proxy at the Meeting.

A shareholder who is entitled to cast two or more votes may appoint up to two proxies and may specify the proportion or number of votes each proxy is appointed to exercise.

Proxy appointments and any authorities under which they are signed (or certified copies of those authorities) may be:

- mailed to Computershare Investor Services Pty Limited, GPO Box 242, Melbourne Victoria 3001 Australia; or
- sent by fax to 1800 783 447 (within Australia) or +61 3 9473 2555 (outside Australia).

Alternatively, proxy instructions can be submitted electronically to the Company's share registrar by visiting investorvote.com.au, and Intermediary Online subscribers only (custodians) should visit intermediaryonline.com.

To be effective, a proxy appointment and, if the proxy appointment is signed by the shareholder's attorney, the authority under which the appointment is signed (or a certified copy of the authority), must be received by the Company at least 48 hours before the commencement of the Meeting.

For more information concerning the appointment of proxies and the addresses to which proxy forms may be sent, please refer to the proxy form.

Voting by attorney

A shareholder may appoint an attorney to vote on their behalf. For an appointment to be effective for the Meeting, the instrument effecting the appointment (or a certified copy of it) must be received by the Company at its registered office or the address listed above for the receipt of proxy appointments at least 48 hours before the commencement of the Meeting.

Corporate representatives

A body corporate which is a shareholder, or which has been appointed as a proxy, may appoint an individual to act as its representative at the Meeting. The appointment must comply with the requirements of section 250D of the Corporations Act. The representative should ensure that a copy of their appointment, including any authority under which it is signed, has been provided to the Company's share registrar in sufficient time before the Meeting.

By order of the Board

C Lewis

Corey Lewis
Company Secretary

11 September 2026

Explanatory Notes

Item 1:

Annual Reports

A copy of the Company's 2026 Annual Report, including the Financial Report, the Sustainability Report and the Reports of the Directors and the Auditor for the year ended 28 June 2026, can be found on the Company's website at investors.babybunting.com.au. It was first released to ASX on 14 August 2026.

Shareholders may elect to receive by mail, free of charge, the Company's 2026 Annual Report. Please contact the Company's share registrar, Computershare, to request a hard copy. The Company mails a copy of the Annual Report only to those shareholders who have made an election to receive it.

Item 2:

Election of Directors

Having last been re-elected at the 2023 Annual General Meeting, Donna Player retires and seeks re-election at the 2026 Annual General Meeting.

Gary Levin was also re-elected at the 2023 Annual General Meeting. After having served as a director since August 2014, he has determined not to seek re-election at the 2026 Annual General Meeting. Accordingly, his term as a director will conclude at the end of the meeting.

As part of the Board's succession planning, Richard Vincent was appointed as a Non-Executive Director on 1 September 2026. Having been appointed a director since the last annual general meeting, Richard Vincent will seek election at the 2026 Annual General Meeting.

Each Director has specifically confirmed to the Company that they will have sufficient time to fulfil their responsibilities as a Director if elected or re-elected.

Item 2(a): To re-elect Donna Player

Donna Player was first appointed a Director of the Company in December 2018. The Board considers Donna to be an independent non-executive director. Donna is a member of the People, Culture and Remuneration Committee. Donna has over 40 years' experience in retail, marketing and product development gained in both retail and wholesale industries. Currently she is Director of Merchandise for Camilla Australia and has had executive responsibilities for merchandise, planning, branding, sourcing and supplier strategies in previous roles.

Donna holds a Bachelor of Arts from the University of NSW and is a graduate of the Australian Institute of Company Directors.

She is currently a non-executive director of Accent Group Limited (appointed in November 2017).

Item 2(b): To elect Richard Vincent

Richard Vincent was first appointed a Director in September 2026. The Board considers Richard to be an independent non-executive director. He is a member of the Audit and Risk Committee.

Richard has over 30 years' executive and board experience across retail and wholesale businesses, with particular strengths in business transformation and finance. He spent over 18 years with Australian Pharmaceutical Industries Limited, the ASX-listed health and beauty retailer and pharmaceutical wholesaler including as Chief Executive Officer and Managing Director from 2017, leading the company through a period of significant growth and its acquisition by Wesfarmers in 2022. Earlier in his career he held senior finance and operational roles. He is currently Chair of the National Pharmaceutical Services Association.

Richard holds a Bachelor of Business (Accountancy) from the University of South Australia and is a Certified Practising Accountant.

Board recommendation: The Board (excluding the relevant director seeking election or re-election because of their interest) endorses the re-election of Donna Player as a Director and the election of Richard Vincent as a Director.

Item 3:

Adoption of the Remuneration Report

As required by the Corporations Act, the Board presents the Remuneration Report to shareholders for consideration and adoption as a non-binding vote.

Among other things, the Remuneration Report contains:

- information about the Board policy for determining the nature and amount of remuneration of the Company's Directors and other KMP;
- remuneration details for KMP for the period ended 28 June 2026; and
- details of the changes that have been made to the Company's executive remuneration arrangements since the last Meeting.

The Remuneration Report, which is part of the 2026 Annual Report, can be found on the Company's website at investors.babybunting.com.au or can be obtained by contacting the Company's share registrar, Computershare.

Voting exclusions apply to this resolution as noted in the Voting at the Meeting section of the Notice of Meeting. If you intend to appoint a member of the Company's KMP (including any Director or the Chair) or any of their closely related parties as your proxy, please refer to the Voting at the Meeting section on pages 4 and 5.

Board recommendation: The Board considers that the remuneration policies adopted for the Company are appropriate and reasonable as they are structured to provide incentives and rewards that are linked to the Company's financial performance and strength. On this basis, the Board recommends that shareholders eligible to do so vote in favour of Item 3.

Item 4:

Grant of share rights to the CEO as deferred equity for his FY2026 Short Term Incentive payment

The Company is asking shareholders to approve a proposed grant of 166,714 share rights to the Company's Chief Executive Officer (CEO), Mark Teperson, on the terms and conditions set out below.

Background

The Company operates short term incentive plans (**STI Plans**) for eligible employees, including the CEO, Mark Teperson.

Key terms of the FY2026 deferred STI Plan and share rights granted under the STI Plan

It is proposed that Mark Teperson be granted 166,714 share rights, which represents his total FY2026 STI Plan award of $393,446. The number of rights was determined by dividing $393,446 by the volume weighted average price of the Company's shares traded on ASX during August 2025, being $2.36.

The entire FY2026 STI award is being delivered as deferred equity. No part of the FY2026 STI is being paid in cash.

The share rights will have a vesting period that ends on 1 August 2027. At the end of that period, the share rights vest and become exercisable. Subject to certain exceptions, the vesting of these share rights is conditional upon Mark's continued employment with the Company (see "Treatment on cessation of employment" below).

The share rights are granted to satisfy a payment to Mark Teperson under the STI Plan.

The Board has decided to use share rights to satisfy the obligation to provide Mark Teperson with his STI Plan award, as providing his STI Plan award as equity (rather than cash) seeks to ensure a greater alignment between Mark's interests and the interests of shareholders. The deferral element is achieved, as the right will only vest and become exercisable in the future if, subject to certain exceptions, Mark is employed on the vesting date.

The terms of the share rights are governed by the Company's long term incentive plan (**LTI Plan**), which established the structure of the Company's equity incentive plans. The key terms of the LTI Plan that are applicable to the share rights are summarised below.

Payment on vesting

No amount is payable upon exercise of a vested share right. Upon exercise, the Company will provide the participant with a fully paid ordinary share. Shares may be issued or purchased on-market for the participant.

Once a share right has vested, the participant will have two years in which to exercise the vested right and be provided with a fully paid ordinary share. Vested rights that have not been exercised at the end of that period will lapse.

The CEO is subject to the Company's minimum shareholding policy, under which he is required to achieve and maintain a shareholding equivalent to 100% of his fixed annual remuneration (salary inclusive of superannuation) within five years from his date of appointment in October 2023. As at the date of this notice, Mark Teperson has a shareholding that exceeds this requirement.

Treatment on cessation of employment

Please refer to the summary of the LTI Plan at Schedule 1.

Shareholder approval has been obtained for the purposes of sections 200B and 200E of the Corporations Act to permit the Company to give a benefit to a participant who holds a managerial or executive office in certain circumstances. This approval was expressed to be for the period up to the 2027 Annual General Meeting.

Treatment on change of control

Please refer to the summary of the LTI Plan at Schedule 1.

New issues and bonus issues

Please refer to the summary of the LTI Plan at Schedule 1.

Malus and clawback

The terms of the share rights provide for malus to be applied to unvested awards and for clawback provisions to be applied for vested awards. This is to ensure that in the event of serious misconduct or the identification of a serious adverse subsequent event, the relevant participant does not inappropriately benefit in those circumstances.

Further information regarding the FY2026 STI Plan and the STI Plan award to Mark Teperson are set out in the 2026 Remuneration Report.

What will happen if the resolution is, or is not, approved?

If shareholder approval is obtained under ASX Listing Rule 10.14, the issue of share rights to Mark Teperson (and any subsequent issue of shares upon exercise of the vested share rights) will not count towards the Company's capacity to issue equity securities under ASX Listing Rule 7.1.

Accordingly, approval is sought for the grant of 166,714 share rights to Mark Teperson as his deferred equity payment for the FY2026 STI Plan.

If approval is not obtained, then the Board will consider alternative arrangements to appropriately remunerate Mark, including payment in cash.

Other information

The Company provides the following additional information to shareholders in accordance with ASX Listing Rule 10.15:

- Mark Teperson is a Director of the Company and as such he comes within ASX Listing Rule 10.14.1. He is the only Director entitled to participate in the Company's equity incentive plans as he is an executive Director.
- It is proposed that Mark Teperson be issued with 166,714 share rights pursuant to this resolution, entitling him to a maximum of 166,714 ordinary shares in the Company if these share rights subsequently vest.
- The details of the remuneration framework applying to Mark Teperson and his current remuneration consist of:
  - salary and superannuation (FAR) of $940,800 (effective 1 September 2026);
  - an opportunity to receive a payment of up to 100% of FAR after the conclusion of FY2027 under the Company's short-term incentive plan for FY2027. Any payment may be a mix of cash and share rights (subject to the approval of shareholders after the conclusion of FY2027). The general structure of the plan is described in the 2026 Remuneration Report. Whether a payment is received is subject to the Company achieving growth targets as well as specific KPIs; and
  - participation in the Company's LTI Plan, being a maximum amount of 150% of FAR.
- Following shareholder approval, Mark Teperson has received the rights described below:

Shareholder approval	Rights
2023 Annual General Meeting	467,289 service rights (of which 311,526 have subsequently vested and were exercised in October 2024 and 2025). 612,980 performance rights at no cost, under the LTI Plan. These rights have lapsed as the applicable performance conditions were not met. As a result, no shares were provided to Mark Teperson.
2024 Annual General Meeting	1,696,707 performance rights at no cost, under the LTI Plan and the FY24–FY28 grant. This grant represented two years' worth of the CEO's long term incentive opportunity. There was no LTI grant in 2025.
2025 Annual General Meeting	417,908 share rights, entitling him to a maximum of 417,908 ordinary shares in the Company, being the deferred payment in relation to the FY2025 Short Term Incentive plan. These rights vested in August 2026 and shares were provided to Mark Teperson.

- It is the intention of the Board that the FY2026 STI Plan share rights be granted to Mark Teperson by 30 October 2026 (but in any event, not more than three years after the date of the 2026 Annual General Meeting).
- No amount will be payable by Mark Teperson on grant or vesting of the share rights. Upon vesting, no amount is payable by Mark Teperson upon the exercise of vested share rights. Accordingly, the Company attributes no value to the rights. When issued, the rights will have a fair value for accounting purposes and for recognising the employee equity incentive expense.
- The proposed grant of the share rights to Mark Teperson is designed to increase the alignment of his interests

as CEO with those of shareholders by providing an incentive linked to the Company's performance over a 12 month period.

- There is no loan scheme in relation to the share rights (or the shares underlying them).
- Details of any securities issued under the scheme will be published in the relevant Annual Report, along with a statement that approval for the issue was obtained under ASX Listing Rule 10.14. Any additional persons covered by ASX Listing Rule 10.14 who become entitled to participate in the Company's equity incentive plans after this resolution is approved will not participate until approval is obtained under ASX Listing Rule 10.14 at a future meeting.

Voting exclusions apply to this resolution as noted in the Voting at the Meeting section of the Notice of Meeting. If you intend to appoint a member of the Company's KMP (including any Director or the Chair) or any of their closely related parties as your proxy, please refer to the Voting at the Meeting section on pages 4 and 5.

Board recommendation: The Board (excluding Mark Teperson because of his interest) considers that the proposed grant of share rights is appropriate and in the best interests of the Company and its shareholders. The grant strengthens the alignment of Mark's interests with shareholders. On this basis, the Board recommends that shareholders eligible to do so vote in favour of Item 4.

Item 5:

Grant of performance rights to the Chief Executive Officer under the LTI Plan

The Company is asking shareholders to approve a proposed grant of 2,238,075 performance rights to the Company's CEO, Mark Teperson, on the terms and conditions set out below.

The grant represents two years' worth of his Long Term Incentive opportunity and will relate to a four-year performance period to the end of FY2030. If the proposed grant is approved, there will be no separate grant to the CEO under the Company's Long Term Incentive Plan at the 2027 Annual General Meeting (that is, in respect of the FY2028 opportunity).

The Board acknowledges the market practice of single annual grants. Taking into account the circumstances and performance of the Company, as it pursues its current strategy which is based on its Long Range Plan out to FY2030, the Board has chosen to structure the grant to the CEO differently. The Board wishes to provide him with a strong alignment to achieve growth in shareholder value through the execution of the Company's strategy. This strategy is focused on growing market share, growing EBITDA and growing return on invested capital. To date, the Company has been delivering on the early part of that strategy.

Long Term Incentive Plan

The LTI Plan is designed to align the interests of executives and senior employees more closely with the interests of the Company's shareholders by providing an opportunity for eligible employees to receive an equity interest in the Company through the grant of performance rights. If the relevant vesting conditions are satisfied, each right entitles the participant to one fully paid ordinary share in the Company. A summary of the key terms of the LTI Plan is set out at Schedule 1.

To provide an incentive for future periods, it is proposed that long-term incentives be granted, that are measured in relation to the four year period from the conclusion of FY2026 to the conclusion of FY2030. The proposed grant is referred to as the **FY2026–FY2030 LTIP grant**.

Proposed grant

Item 5 is a proposal to grant Mark Teperson 2,238,075 performance rights under the Company's Long Term Incentive Plan as part of the FY2026–FY2030 LTIP grant.

The number of performance rights to be granted to the CEO was determined as

$$\frac{150\% \times (\text{FY27 FAR} + \text{FY28 FAR})}{\text{August 2026 VWAP}}$$

where FY27 FAR is the CEO's fixed annual remuneration (salary inclusive of superannuation) (**FAR**) of $940,800 and FY28 FAR is that amount increased by 3%, being $969,024. August 2026 VWAP represents the volume weighted average price of the Company's shares traded on ASX during August 2026, being $1.28.

The Board believes that the offer of performance rights under the FY2026–FY2030 LTIP grant is an important part of the CEO's remuneration and provides alignment with the pursuit of long-term shareholder value and, specifically, the execution of the Company's new strategy.

As the above amount reflects two years' worth of the CEO's long-term incentive opportunity (FY2027 and FY2028), there will be no further grant to the CEO under the Company's LTIP at the 2027 Annual General Meeting if Item 5 is approved.

The award of performance rights means that the actual value (if any) of shares the CEO will receive from this grant is not determined until the end of the performance period and will depend on the extent to which the two performance conditions are achieved, and (if vesting occurs) the share price at the time shares are provided to him.

The terms that apply to the FY2026–FY2030 LTIP grant are described below.

Two performance conditions

For the FY2026–FY2030 LTIP grant:

- 40% of the rights will be subject to the return on funds employed (**ROFE**) condition; and
- 60% of the rights will be subject to the total shareholder return (**TSR**) compound annual growth (**CAGR**) condition.

The Board has selected these two conditions having regard to the aim to focus on:

- growing the Company's earnings in a capital efficient manner; and
- growing shareholder value as measured by share price appreciation and dividends provided.

Performance condition 1 – ROFE

ROFE will be measured as the Company's Net Operating Profit Before Tax divided by Funds Employed, expressed as a percentage.

Net Operating Profit Before Tax (**NOPBT**) will be calculated as profit before tax, after adding back interest on borrowings, deducting interest income and adding back any significant items before tax. This measure has been selected as it reflects underlying earnings and retains accountability for any significant items through the add-back to the funds employed amount. Lease related depreciation and interest costs are included in the net operating profit amount.

Funds Employed will be the sum of the opening balance of shareholders' equity, net debt and significant items after tax that have been excluded from NOPBT. The amount of any final dividend declared in respect of the year prior to the final year of the performance period (but which is paid in that final year), would also be excluded from Funds Employed. Opening Funds Employed (rather than closing or average) will be used; as returns from any capital deployed during the performance period are mostly delivered in subsequent periods. For example, investments in new store openings and refurbishments materially occur after the first year as the store's sales performance matures after the initial year of opening. However, all of the capital for the new store is deployed in advance of the store commencing trading.

The Company's ROFE calculated on the above basis has been:

	FY20	FY21	FY22	FY23	FY24	FY25	FY26
ROFE	28.7%	31.8%	31.6%	18.4%	5.8%	12.1%	15.1%

The results for FY2020, FY2021 and FY2022 occurred during the unusual trading conditions experienced during the COVID period which saw elevated sales performance in some categories. The FY2021 ROFE calculation has been normalised for abnormally low inventory levels at the end of FY2020, driven by an unprecedented short term spike in demand following the end of the first national COVID lockdown.

The number of performance rights that vest for a performance period will be determined having regard to ROFE in FY2030, as follows:

- if FY2030 ROFE is less than 19% – no ROFE performance rights vest;
- if FY2030 ROFE is 19% – then 30% of the ROFE performance rights vest;
- if FY2030 ROFE is 26% – then 66.67% of the ROFE performance rights vest; and
- if FY2030 ROFE is 30% or more – then 100% of the ROFE performance rights vest.

If the FY2030 ROFE is between any levels above, then vesting will occur on a straight-line pro rata basis applicable to the ROFE performance between those levels.

Performance condition 2 – TSR compound annual growth

Broadly, the TSR performance condition will assess the increase in the Company's share price (assuming dividends are reinvested). TSR will be measured as the increase in the Company's share price from a reference share price, being the volume weighted average price of the Company's shares on ASX during August 2026, being $1.28. Growth in the Company's share price will be measured by reference to the volume weighted average price during August 2030.

The number of performance rights that vest for a performance period will be determined as follows:

- if the TSR CAGR is less than 10% – no TSR performance rights vest;
- if the TSR CAGR is 10% – then 30% of the TSR performance rights vest;
- if the TSR CAGR is 20% – then 66.67% of the TSR performance rights vest; and
- if the TSR CAGR is 30% or above – then 100% of the TSR performance rights vest.

If TSR CAGR is between two of the levels above, then vesting will occur on a straight-line pro rata basis applicable to the TSR CAGR performance between those levels.

Accelerated vesting for exceptional performance

The Board considers that the two performance conditions provide challenging measures across the four year performance period aligned to accelerating the Company's growth and driving shareholder value.

As an additional incentive and to reward exceptional performance, accelerated vesting may be available for up to half of the performance rights granted to the CEO. Accelerated vesting will occur if the ROFE or TSR CAGR performance conditions, as applicable, are met at the end of FY2029. For example, if ROFE at the end of FY2029 is 19%, then up to 15% of the ROFE performance rights will be available for vesting – that is, 50% of the 30% of ROFE performance rights that vest at threshold ROFE performance. The balance of the performance rights will remain on foot for testing at the end of FY2030.

Payment on vesting

No amount is payable upon exercise of a vested performance right. Upon exercise, the Company will provide the participant with a fully paid ordinary share. Shares may be issued or purchased on-market for the participant.

Once a performance right has vested, the participant will have two years in which to exercise the vested right and be provided with a fully paid ordinary share. Vested rights that have not been exercised at the end of that period will lapse.

The CEO is subject to the Company's minimum shareholding policy, under which he is required to achieve and maintain a shareholding equivalent to 100% of his FAR within five years from his date of appointment in October 2023. As at the date of this notice, Mark Teperson has a shareholding that exceeds this requirement.

Treatment on cessation of employment

Please refer to the summary of the LTI Plan at Schedule 1.

Shareholder approval has been obtained for the purposes of sections 200B and 200E of the Corporations Act to permit the Company to give a benefit to a participant who holds a managerial or executive office in certain circumstances. This approval was expressed to be for the period up to the 2027 Annual General Meeting.

Treatment on change of control

Please refer to the summary of the LTI Plan at Schedule 1.

New issues and bonus issues

Please refer to the summary of the LTI Plan at Schedule 1.

Malus and clawback

The terms of the performance rights provide for malus to be applied to unvested awards and for clawback provisions to be applied for vested awards. This is to ensure that in the event of serious misconduct or the identification of a serious adverse subsequent event, the relevant participant does not inappropriately benefit in those circumstances.

What will happen if the resolution is, or is not, approved?

If shareholder approval is obtained under ASX Listing Rule 10.14, the issue of performance rights to Mark Teperson will not count towards the Company's capacity to issue equity securities under ASX Listing Rule 7.1.

Accordingly, approval is sought for the grant of 2,238,075 performance rights (ie the maximum that could vest) to Mark Teperson under the FY2026-FY2030 LTIP grant.

If approval is not obtained, then the Board will have regard to developing alternative remuneration arrangements for Mark to provide him with an appropriate long term incentive.

Other information

The Company provides the following additional information to shareholders in accordance with ASX Listing Rule 10.15:

- Mark Teperson is a Director of the Company and as such he comes within ASX Listing Rule 10.14.1. He is the only Director entitled to participate in the Company's LTI Plan.
- It is proposed that Mark Teperson be issued with 2,238,075 performance rights under the FY2026-FY2030 LTIP grant, entitling him to a maximum of 2,238,075 shares in the Company if all of these performance rights subsequently vest.
- The details of the remuneration framework applying to Mark Teperson and his current remuneration, and the rights previously granted to him, are described in the Other Information for Item 4.
- It is the intention of the Board that the performance rights be granted to Mark Teperson by 30 October 2026 (but in any event, not more than three years after the date of the 2026 Annual General Meeting).
- No amount will be payable by Mark Teperson on grant or vesting of the performance rights. If vesting occurs, no amount is payable by Mark upon the exercise of vested performance rights.
- There is no loan scheme in relation to the performance rights (or the shares underlying them).
- Details of any securities issued under the scheme will be published in the relevant Annual Report, along with a statement that approval for the issue was obtained under ASX Listing Rule 10.14. Any additional persons covered by ASX Listing Rule 10.14 who become entitled to participate in the LTI Plan after this resolution is approved will not participate until approval is obtained under ASX Listing Rule 10.14 at a future meeting.

Board recommendation: The Board (excluding Mark Teperson because of his interest) considers that the proposed grant of performance rights is appropriate and in the best interests of the Company and its shareholders. The grant strengthens the alignment of Mark's interests with shareholders and provides an incentive linked to continued growth of the Company's earnings and share price over the next four years. On this basis, the Board recommends that shareholders eligible to do so vote in favour of Item 5.

Item 6:
Approval of the Long Term Incentive Plan

The Company seeks shareholder approval for the purposes of ASX Listing Rule 7.2, Exception 13(b), section 260C(4) of the Corporations Act, and for all other purposes, to approve:

- the LTI Plan;
- the grant of any rights under the LTI Plan; and
- the issue of underlying shares for such rights in accordance with the LTI Plan,

on the terms and conditions described in this Explanatory Note.

ASX Listing Rule 7.1 provides that a listed company must not, without prior approval of its shareholders, issue or agree to issue securities if the number of securities issued or agreed to be issued, or when aggregated with the number of shares issued by the Company during the 12 months immediately preceding the date of issue or agreement, exceeds 15% of the number of shares on issue at the start of that 12 month period.

Listing Rule 7.2, Exception 13(b) provides an exception to ASX Listing Rule 7.1 such that an issue of securities under an employee incentive scheme will not be counted towards the 15% limit if, within three years before the issue date, ordinary shareholders approved the issue of equity securities under the scheme as an exception to Listing Rule 7.1 in accordance with the Listing Rules.

This is the first time the Company is seeking shareholder approval of the LTI Plan. 28,562,798 securities, being rights, have been allocated under the LTI Plan since the Company was admitted to the official list of ASX on 13 October 2015, of which 12,125,716 have lapsed or been cancelled and 6,033,022 are currently outstanding.

For the purpose of this item, the maximum number of equity securities proposed to be issued under the LTI Plan within the three-year period from the date of the passing of Item 6 is 13,000,000 rights representing 9.5% of the undiluted shares in the Company as at 1 September 2026. This maximum number is not intended to be a prediction of the actual number of rights to be issued under the LTI Plan, but simply a maximum number to set a ceiling for the purposes of the Listing Rule 7.2, Exception 13(b) approval. The Company wishes to preserve flexibility to issue additional securities within the three-year approval period without having to obtain shareholder approval under Listing Rule 7.1.

If shareholders approve Item 6, any issue of securities under the LTI Plan during the three-year period after the Meeting will not be counted towards the Company's 15% placement capacity. However, Exception 13(b) does not apply to Directors and their associates, who are deemed related parties of the Company, and issues to such persons will require separate approval under Listing Rule 10.14.

If the Company's shareholders do not approve Item 6, the issue of securities under the LTI Plan will be included in calculating the Company's 15% capacity for the purposes of ASX Listing Rule 7.1, effectively decreasing the number of equity securities the Company can issue without shareholder approval over the 12-month period following the issue of the securities.

Background

In line with the Company's remuneration strategy, the Board's view is that an equity-based incentive is a key component of the "at-risk" remuneration arrangements for employees. As such, the Directors seek authorisation to issue rights under the LTI Plan in accordance with ASX Listing Rule 7.2, Exception 13(b) so that any rights issued under the LTI Plan will be excluded from the maximum number of securities that may be issued by the Company in any 12 month period, for a period of three years from the date of this Meeting.

The Board considers it desirable to maintain this flexibility to retain additional placement capacity through subsequent issues should they be required. **There is no current intention to undertake a capital raising or a placement.**

The Company is also seeking shareholder approval of the LTI Plan in order that it may obtain the benefit of the exemption in section 260C(4) of the Corporations Act for financial assistance provided under an employee share scheme approved by shareholders.

A summary of the terms of the LTI Plan is set out in Schedule 1.

Board recommendation: The Board (excluding Mark Teperson because of his interest), unanimously recommends that shareholders vote in favour of Item 6.

Schedule 1:
Long Term Incentive Plan Overview

The following is a summary of material terms of the Baby Bunting Group Limited Long Term Incentive Plan (**Plan**).

1. Object of the Plan

The Plan is to assist in the recruitment, reward, retention and motivation of employees by providing the Board with the ability to offer a long-term incentive to an employee in the form of the grant of rights under the Plan. Under the Plan, eligible employees may be entitled to exercise rights subject to the achievement of certain terms and conditions (including performance and service conditions) or the satisfaction of any restrictions (including disposal restrictions), that the Board may determine from time to time. The Plan is administered by the Board (or its delegates) in its discretion.

2. Participation

All permanent full-time and part-time employees of the Company and its related bodies corporate (excluding non-executive Directors) are eligible to participate in the Plan. An **eligible employee** is an employee whom the Board determines is to receive an offer under the Plan.

3. Offers

The Board may from time to time, in its absolute discretion, decide to make an offer to any eligible employee to be provided with one or more rights and may determine the terms of the offer, including the number of rights to be granted and the vesting conditions (if any) imposed on the right of a participant to exercise any right granted. A right means either an option or a right granted pursuant to the Plan rules to acquire one fully paid ordinary share in the Company (**Share**), subject to the terms of the Plan rules and the terms of the offer.

Each offer must be in writing and must specify the eligible employee to whom the offer is made, the form of the right (that is, either an option or a right), the number of rights being offered (or formula for calculation), the right exercise price (if any), the date by which the offer must be accepted and the manner of acceptance, the vesting conditions and any disposal restrictions, and any undertakings or information required by the Corporations Act or ASIC Instrument. No amount is payable on the grant of any right. Offers are personal to the eligible employee to whom they are made. The Company must not make an offer if making the offer would breach any issue limit set out in the Corporations Act or any applicable ASIC Instrument.

4. Grant of Rights

To accept an offer, an eligible employee must, on or before the closing date stated in the offer, do what is specified in the offer to accept it. By accepting an offer, a participant agrees to be bound by the terms of the offer, the Plan rules and the Company's Constitution, and if Shares are acquired upon exercise of the rights, to become a member of the Company.

The Company has discretion whether to treat an offer as accepted, and an offer will not be treated as accepted if the person to whom the offer was made is not an employee at the time, or if either the Company or the employee has given notice terminating the employee's employment prior to the acceptance date. An eligible employee does not have to pay money or give other consideration for the grant of a right. Upon granting rights to a participant, the Company must record details of the rights in a register and issue the holder a holding statement or other record of the number of rights granted.

5. No Transfer of Rights

The rights will not be listed on any securities exchange. Each right is personal to the participant and is not transferable, transmissible or assignable, and must not be encumbered, except in accordance with the Board's discretion on ceasing employment under rule 9.3 of the Plan rules.

6. Vesting and Exercise of Rights

A participant will be entitled to exercise rights granted as a result of an offer in respect of which all vesting conditions have been satisfied (or waived by the Company) and which are otherwise capable of exercise in accordance with the terms of the relevant offer and the Plan rules. The Company will determine whether the vesting conditions for a right have been satisfied and must give written notice to the participant stating the number of rights that have become exercisable.

A participant may only exercise rights by delivery to the Company of a signed notice stating that the participant exercises the rights and specifying the number of rights being exercised, together with payment of the right exercise price (if any). Once a right is capable of exercise, it may be exercised at any time up until the day that is no later than seven years after the date of grant of the right or any earlier date specified in the terms of grant. If the items specified in the Plan rules for exercise are delivered, the Company will instruct the trustee to subscribe for, acquire or allocate to the participant the relevant Shares. The trustee will hold those Shares as trustee for and on behalf of the participant as beneficial owner, subject to the terms of the trust deed, and will transfer to the participant the Shares allocated to and held on behalf of that participant, subject to any disposal restrictions. Shares issued by the Company in connection with the exercise of a right will rank equally in all respects with Shares already on issue.

From the date of acquisition by the trustee, the participant will be the beneficial owner of those Shares and will be absolutely and indefeasibly entitled to any dividends paid in respect of those Shares.

While the Shares are quoted on ASX, the Company will apply for quotation of Shares issued upon exercise of a right in accordance with the ASX Listing Rules.

7. Lapse

Subject to the terms of the offer, a participant's rights will lapse on the earlier of: the expiry of the exercise period; if the vesting conditions have not been satisfied (or waived) or are unable to be met by the relevant time specified in the offer; in accordance with the treatment on ceasing employment provisions; if the Board becomes aware of circumstances which, in the reasonable opinion of the Board, indicate that the participant has acted fraudulently, dishonestly or in breach of his or her obligations to the Company or any group member and determines that the right lapses; or if the Company commences to be wound up and the Board has not otherwise exercised its discretion under the takeover provisions.

8. Takeovers and Arrangements

If a takeover bid is made and recommended by the Board or declared unconditional, a Court orders a meeting in relation to a proposed scheme of arrangement, any person becomes bound or entitled to compulsorily acquire shares, there has been a change of control of the Company, the Company passes a resolution for voluntary winding up or an order is made for compulsory winding up, the Board may, in its absolute discretion, resolve that some or all of the unexercised rights (whether vested or not) will be exercisable. The Board's discretion includes a discretion to determine that any relevant vesting condition is to be tested at that time and that the number of rights that may be exercised is to reflect the extent to which any relevant vesting condition is (or may have been) satisfied or the period during which the rights have been held. In respect of rights that are already exercisable, the Board must resolve that all of the unexercised rights are to be exercised within the time specified by the Board.

9. Treatment on Ceasing Employment

If a participant ceases to be an employee after a right has become exercisable (and before the lapsing date), the participant will be entitled to exercise those rights for a period of up to 60 days after the cessation date, after which the rights will lapse.

If a participant ceases to be an employee before a right has become exercisable due to resignation (other than due to serious illness or total permanent incapacitation (as determined by the Board)), a group member exercising a right to terminate the participant's employment with immediate effect, or any other circumstance (other than serious illness, total permanent incapacitation (as determined by the Board), genuine redundancy or any other circumstance determined by the Board), then all rights granted to the participant will lapse on the cessation date, unless the Board determines otherwise. If a participant ceases employment for a reason other than those specified above, the participant may retain a proportion of the rights (equal to the proportion of the time elapsed in respect of any applicable vesting condition, or such other time as the Board may determine), and all other rights will lapse. Notwithstanding these provisions, the Board may determine that some or all of the rights held by a participant do not lapse and may be exercised within such additional time as is determined by the Board. An offer may provide for different treatment of rights upon a participant ceasing to be an employee.

10. Trustee

The Company may determine and conclude agreements with the trustee, and enforce or prosecute any rights and obligations under such agreements, without reference or recourse to participants. The Company may provide funds to the trustee to subscribe for or acquire Shares, pay the trustee for services, remove the trustee and appoint a new trustee, and otherwise exercise any rights under the trust deed. The Company may determine how any costs associated with the trustee are to be borne.

11. Adjustments

Subject to the ASX Listing Rules, a participant may only participate in a new issue of Shares or other securities if the right has been exercised and Shares are allotted or transferred on or before the record date. If the Company makes a pro rata issue of securities (except a bonus issue), the right exercise price will be reduced according to the formula specified in the ASX Listing Rules. If the Company makes a pro rata bonus issue, the participant will be entitled upon later exercise of the right to receive additional Shares. If the Company reorganises its issued capital, the Board will determine the effect on unexercised rights, provided the participants will not receive a benefit which shareholders do not receive. Adjustments must be consistent with the ASX Listing Rules.

12. Administration

The Plan will be administered by the Board in accordance with the Plan rules. The Board may make regulations for the operation of the Plan which are consistent with the Plan rules. Every exercise of discretion by the Board (or its delegate) and every decision as to the interpretation, effect or application of the Plan rules is final, conclusive and binding. The Board may delegate its powers to a committee of Directors or one or more persons selected by the Board.

13. Duration

The Plan continues in operation until the Board decides to end it. The Board may suspend the operation of the Plan for a fixed period or indefinitely, and may end any suspension. If the Plan ends or is suspended for any reason, that does not prejudice the accrued rights of participants.

14. Amendment

Subject to the ASX Listing Rules, the Company may at any time by written instrument or by resolution of the Board amend all or any of the provisions of the Plan rules. No amendment may reduce the rights of any participant, other than an amendment introduced primarily: for the purpose of complying with present or future legislation; to correct any manifest error or mistake; to enable compliance with the Corporations Act, the ASX Listing Rules, applicable foreign law, or a requirement of ASIC or other regulatory body; or to provide for a trustee to hold restricted Shares on behalf of participants. Notwithstanding this restriction, the Company may amend the Plan rules provided it provides appropriate compensation to any affected participant so that the participant remains no worse off.

15. Taxation

If a group company is required to pay an amount to an authority for tax (other than payments made in relation to payroll tax, fringe benefits tax or payments ordinarily required to be made in relation to the superannuation guarantee) in relation to the offer, rights or Shares allocated, issued or transferred on exercise of a right, the Company may recover an amount in respect of the tax from the participant in such manner as the Board thinks fit. The participant may be required as a condition of the grant or vesting of the right or the allocation, issue, sale or transfer of Shares to indemnify the group company, make a payment, or enter into an arrangement to secure a payment, including by providing authority for the sale of some or all of the Shares. If a participant fails to comply, the participant's rights will lapse and the participant's interest in the Shares will be forfeited.

16. General Provisions

Nothing in the Plan rules confers on an eligible employee the right to receive any Shares, confers on a participant the right to continue as an employee, confers on a participant the right to encumber the rights, or affects any rights of any group company to terminate the employment of any employee. The Plan rules, the offering and granting of any rights, the rights attaching to the rights granted and the issue or acquisition of any Shares pursuant to the exercise of rights will at all times be subject to the Corporations Act, the Income Tax Assessment Act 1997 (Cth) and any other applicable legislation and, while the Shares are quoted, the ASX Listing Rules. No right may be granted to or vest in a participant if to do so would contravene the Corporations Act or the ASX Listing Rules. The Plan is governed by the law in force in Victoria.

BabyBunting

BabyBunting

Baby Bunting Group Limited
ABN 58 128 533 693

Need assistance?

Phone:
1300 850 505 (within Australia)
+61 3 9415 4000 (outside Australia)

Online:
www.investorcentre.com/contact

YOUR VOTE IS IMPORTANT

For your proxy appointment to be effective it must be received by **10.00am (Sydney time) on Sunday, 11 October 2026.**

Proxy Form

How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

APPOINTMENT OF PROXY

Voting 100% of your holding: Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote or abstain as they choose (to the extent permitted by law). If you mark more than one box on an item your vote will be invalid on that item.

Voting a portion of your holding: Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%.

Appointing a second proxy: You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

A proxy need not be a securityholder of the Company.

SIGNING INSTRUCTIONS FOR POSTAL FORMS

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held. Delete titles as applicable.

PARTICIPATING IN THE MEETING

Corporate Representative
If a representative of a corporate securityholder or proxy is to participate in the meeting you will need to provide the appropriate "Appointment of Corporate Representative". A form may be obtained from Computershare or online at www.investorcentre.com/au and select "Printable Forms".

Lodge your Proxy Form:

Online:

Lodge your vote online at www.investorvote.com.au using your secure access information or use your mobile device to scan the personalised QR code.

Your secure access information is

Control Number: 188961

SRN/HIN:

For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com

By Mail:

Computershare Investor Services Pty Limited
GPO Box 242
Melbourne VIC 3001
Australia

By Fax:

1800 783 447 within Australia or
+61 3 9473 2555 outside Australia

PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.

☐ **Change of address.** If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with '**X**') should advise your broker of any changes.

Proxy Form

Please mark ☒ to indicate your directions

Step 1 Appoint a Proxy to Vote on Your Behalf

I/We being a member/s of Baby Bunting Group Limited hereby appoint

☐ **the Chair of the Meeting** **OR** ____________________

PLEASE NOTE: Leave this box blank if you have selected the Chair of the Meeting. Do not insert your own name(s).

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chair of the Meeting, as my/our proxy to act generally at the meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, and to the extent permitted by law, as the proxy sees fit) at the Annual General Meeting of Baby Bunting Group Limited to be held at Cliftons Sydney, Level 13, 60 Margaret St, Sydney NSW 2000 on Tuesday, 13 October 2026 at 10.00am (Sydney time) and at any adjournment or postponement of that meeting.

Chair authorised to exercise undirected proxies on remuneration related resolutions: Where I/we have appointed the Chair of the Meeting as my/our proxy (or the Chair becomes my/our proxy by default), I/we expressly authorise the Chair to exercise my/our proxy on Items 3, 4, 5 and 6 (except where I/we have indicated a different voting intention in step 2) even though Items 3, 4, 5 and 6 are connected directly or indirectly with the remuneration of a member of key management personnel, which includes the Chair.
Important Note: If the Chair of the Meeting is (or becomes) your proxy you can direct the Chair to vote for or against or abstain from voting on Items 3, 4, 5 and 6 by marking the appropriate box in step 2.

Step 2 Items of Business

PLEASE NOTE: If you mark the **Abstain** box for an item, you are directing your proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.

		For	Against	Abstain
Item 2(a)	To re-elect Donna Player	☐	☐	☐
Item 2(b)	To elect Richard Vincent	☐	☐	☐
Item 3	Adoption of the Remuneration Report	☐	☐	☐
Item 4	Approval of the grant of share rights to the CEO as deferred equity for his FY2026 Short Term Incentive payment	☐	☐	☐
Item 5	Approval of the grant of performance rights to the CEO under the Company's Long Term Incentive Plan	☐	☐	☐
Item 6	Approval of the Long Term Incentive Plan	☐	☐	☐

The Chair of the Meeting intends to vote undirected proxies in favour of each item of business. In exceptional circumstances, the Chair of the Meeting may change her/his voting intention on any resolution, in which case an ASX announcement will be made.

Step 3 Signature of Securityholder(s)

This section must be completed.

Individual or Securityholder 1	Securityholder 2	Securityholder 3	
			/ /
Sole Director & Sole Company Secretary	Director	Director/Company Secretary	Date

Update your communication details *(Optional)*

By providing your email address, you consent to receive future Notice of Meeting & Proxy communications electronically

Mobile Number	Email Address

computershare